Kornimate/medical-research-clean huggingface dataset:
an observational study of perioperative immunotherapy in msi-h gastrointestinal tumors

Conditions: To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer

Summary: gastrointestinal cancer like gastric cancer and colorectal cancer are high-incidence tumors worldwide. surgery is the only curable way. perioperative treatment can improve the survival of patients. microsatellite instability-high（msi-h）are a special subtype of gastrointestinal tumors, accounting for about 15-22%. according to current research, patients with this type of gastrointestinal tumors cannot benefit from traditional perioperative chemotherapy, which directly affects the long-term survival of patients. because patients with msi-h have a unique tumor immune microenvironment, thus they are more likely to benefit from immunotherapy. current studies have confirmed that the use of immunotherapy during palliative care can prolong the survival of patients with msi-h. in the neoadjuvant treatment stage, according to the previous clinical practice of our center, the use of immunotherapy can make some patients achieve complete postoperative pathological remission. however, in the perioperative treatment stage, the value of immunotherapy is still lack of powerful clinical evidence. based on this, our group intends to start an observational study to prospectively enroll patients with msi-h gastrointestinal tumor using immunotherapy during the perioperative period.the primary endpoint is safety while survival outcomes as secondary endpoints. in order to evaluate the safety and effectiveness of immunotherapy during the perioperative treatment stage in msi-h gastrointestinal cancer


Eligibility criteria:
inclusion criteria: 1. ≥18 years old,diagnosed as gastric or colorectal cancer by pathology; 2. diagnosed as a mismatch repair deficient by immunohistochemistry,or diagnosed as microsatellite instability-high by polymerase chain reaction(pcr) or next-generation sequencing(ngs); 3. suitable for tumor radical resection; 4. join this trial voluntarily,and could sign an informed consent form; 5. with good compliance. exclusion criteria: 1. do not use immunotherapy containing pd-1/pd-l1 antibody during the perioperative period; 2. simultaneous diagnosis of dual primary tumors, and the second tumor cannot be resected radically, or the second tumor is not dmmr/msi-h; 3. complicate with uncontrollable immune system diseases; 4. patients who need to use glucocorticoids and other immunosuppressive agents for a long time; 5. patients who received live vaccines or live attenuated vaccines within 30 days before the medication, except for inactivated vaccines; 6. those who cannot provide detailed medical records or cannot cooperate with follow-up.
skype for youth with poorly controlled diabetes

Conditions: Type 1 Diabetes

Summary: compared family-based skills training (aka, behavioral family systems therapy) to youth with poorly controlled type 1 diabetes and their parents either face-to-face or over skypetm. examined the differential impact on the youth's adherence to the diabetes medical regimen and the youth's blood sugar control.


Eligibility criteria:
inclusion criteria: * youth between the ages of 12 and 18 with type 1 diabetes characterized by an hba1c value great than 9% * caregivers willing to participate * family members reading english at 5th grade level * willing to be randomized. exclusion criteria: * youth with intellectual disability * parent or youth who doesn't speak english
reducing pediatric obesity through after-school programs

Conditions: Obesity

Summary: this study will assess the impact of a national, community-based after-school program promoting physical activity (america scores) on obesity, fitness and important cardiovascular risk factors among minority children. the investigators central hypothesis is that established community-based programs, such as america scores, can reduce obesity and cardiovascular risk among participants. the 1-year study followed 158 children from 6 public schools, 3 of which were randomized to have scores and 3 to "usual care" after-school program. primary outcomes are change in body mass index (bmi), physical activity (measured by accelerometer), and fitness (aerobic capacity assessed with the 20-meter shuttle test). cardiovascular outcomes include blood pressure, body composition (assessed using bioelectrical impedance) and waist circumference. the investigators will also measure academic outcomes.

baseline measures were collected in september 2009; midpoint measures were collected in january 2010; and final measures were collected in may 2010. repeated measures analyses will compare trajectories for bmi, physical activity, and fitness between students in the scores and the usual care arms.

Eligibility criteria:
inclusion criteria: * 3rd-5th grade student enrolled in after-school program in san francisco unified school district exclusion criteria: * uncontrolled asthma * unable to participate in moderate physical activity

Keywords: obesity minority child physical fitness school physical activity
effect of cpap therapy on lpr among patients with osas

Conditions: Laryngopharyngeal Reflux; Obstructive Sleep Apnea

Summary: this study will investigate the changes in the reflux symptom index (rsi) and reflux finding score (rfs) among patients with obstructive sleep apnea after regular humidified cpap therapy. since these two diseases have strong associations then one may consider the possible benefits from therapy in between them.


Eligibility criteria:
inclusion criteria: * patients have to stop proton pump inhibitors (ppi) therapy 1 month before enrollment in the study. * to be eligible as lpr patients in our study, patients must have presented a rsi score \> 13 and a rfs score \> 7. these thresholds were highly correlated with pathological ph monitoring (ph \< 4) exclusion criteria: * noncompliance for cpap use: according to the standard medicare criteria to define cpap compliance, the patients who demonstrated cpap use ≥ 4 h/ night for ≥ 70% of the nights are considered compliant. * antireflux therapy during the period of the study.
mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease

Conditions: Hematological Malignancies

Summary: mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning from hla-mismatched pbsc or cord blood: a pilot study


Eligibility criteria:
v.1. patients v.1.1. diseases hematological malignancies confirmed histologically and not rapidly progressing: * aml in cr; * all in cr; * cml unresponsive/intolerant to imatinib but not in blast crisis; * other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis; * mds with \< 5% blasts; * multiple myeloma; * cll; * non-hodgkin's lymphoma (aggressive nhl should have chemosensitive disease); * hodgkin's disease. v.1.2. clinical situations * theoretical indication for a standard allo-transplant, but not feasible because: * age \> 55 yrs; * unacceptable end organ performance; * patient's refusal. * indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant. v.1.3. other inclusion criteria * male or female; fertile female patients must use a reliable contraception method; * age \< 75 yrs. * informed consent given by patient or his/her guardian if of minor age. v.1.4. exclusion criteria * any condition not fulfilling inclusion criteria; * hiv positive; * terminal organ failure, except for renal failure (dialysis acceptable); * uncontrolled infection, arrhythmia or hypertension; * previous radiation therapy precluding the use of 2 gy tbi; * hla-identical donor. v.2. pbsc donors v.2.1. inclusion criteria * related to the recipient (sibling, parent or child) or unrelated; * male or female; * weight \> 15 kg (because of leukapheresis); * fulfills generally accepted criteria for allogeneic pbsc donation; * informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures. v.2.2. exclusion criteria * any condition not fulfilling inclusion criteria; * hiv positive; * unable to undergo leukapheresis because of poor vein access or other reasons. v.2.3. hla matching related or unrelated donors who have 1-2 hla mismatches, as either : * one antigenic mismatch at hla-a or -b or -c or -drb1 or -dqb1 * one allelic mismatch at hla-a or -b or -c or -drb1 or -dqb1 * two allelic mismatches at hla-a or -b or -c or -drb1 or -dqb1 * one antigenic mismatch + 1 allelic mismatch at hla-a or -b or -c or -drb1 or -dqb1. * one antigenic mismatch at -dqb1 and one other antigenic mismatch at hla-a or -b or -c or -drb1 v.3. cord blood unit banked cord blood units will be used if they fulfill the following criteria: * no more than 2/6 hla mismatches (antigenic mismatch at hla-a or hla-b or allelic mismatch at hla-drb1) * \> 2.5 x 107 tnc/kg * standard validation by fact/netcord criteria.

Keywords: hct, nonmyeloablative, mesenchymal stem cells, gvhd
levetiracetam versus standard antiepileptic drugs (carbamazepine and valproate) used as monotherapy in patients with newly diagnosed epilepsy

Conditions: Epilepsy

Summary: study n01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (lev) versus the 2 older antiepileptic drugs (aeds), sodium valproate extended release (vpa-er) and carbamazepine controlled release (cbz-cr) in the treatment of subjects with newly diagnosed epilepsy.


Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy (all types of seizures) was made during the past year * subjects must have had at least two unprovoked seizures in the past 2 years with at least one during the last 6 months * female subjects without childbearing potential are eligible. female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method exclusion criteria: * subjects previously allocated to a trial treatment (cbz, vpa and lev) used in this trial * participation in another clinical trial with an investigational drug or device within 12 weeks of the selection visit (v1), or at any time during this trial * pregnant or lactating women * presence of known pseudoseizures within the last year * uncountable seizures (clusters) or history of convulsive status epilepticus * any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs * history of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years * presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors * presence of a terminal illness or any medical condition that might interfere with the subject's trial participation

Keywords: newly diagnosed epilepsy levetiracetam keppra carbamazepine valproate
a study of ak117 in combination with azacitidine in patients with myelodysplastic syndromes

Conditions: Higher-risk Myelodysplastic Syndromes

Summary: this is a phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of ak117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (hr-mds).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old at the time of enrolment. * eastern cooperative oncology group (ecog) performance status score of 0 to 2. * expected life expectancy ≥ 3 months. * newly diagnosed hr-mds, according to the 2016 world health organization (who) classification with the presence of \< 20% blasts in bone marrow or peripheral blood; overall ipss-r score ≥ 3.5. * ability to undergo the study-required bone marrow sample collection procedures. * suitable venous access for the study-required blood sampling (i.e., including pk and immunogenicity). * female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing. * female patients of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 180 days after the last dose of the study treatment. * unsterilized male patients having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 180 days after the last dose of study treatment. exclusion criteria: * mds evolving from a pre-existing myeloproliferative neoplasm (mpn), myelodysplastic/myeloproliferative neoplasms (mds/mpn). * prior treatment with cluster of differentiation (cd) 47 or signal-regulatory protein alpha (sirpα)-targeting agents. * concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. * patients who previously diagnosed with another malignancy and have any evidence of residual disease. * known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies. * patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study. * patients with current hypertension with systolic blood pressure ≥ 160 mmhg or diastolic blood pressure ≥ 100 mmhg after oral antihypertensive therapy. * patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (new york heart association class iii or iv), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders. * patients who are breastfeeding or plans to breastfeed during the study. * other conditions where the investigator considers the patient inappropriate for enrollment.
chances for success of cavatermtm surgery as a function of uterus probe length

Conditions: Menorrhagia

Summary: cavatermtm is a second-generation thermal balloon ablation device in the management of menorrhagia. the purpose of this study is to investigate the success (questionnaire) of cavatermtm dependent on uterus probe length, especially corpus probe length, which is measured during surgery.


Eligibility criteria:
inclusion criteria: * cavatermtm operation because of menorrhagia * timeframe: january 2006 till august 2009 * older than 29 years and younger than 56 years exclusion criteria: * pregnancy * fragmentary filled questionnaire * more than 1 cavatermtm operation

Keywords: menorrhagia dysfunctional uterine bleeding endometrial ablation cavatermtm probe
azathioprine in recurrent implantation failure

Conditions: Recurrent Implantation Failure; In Vitro Fertilization; Intracytoplsmic Sperm Injection

Summary: azathioprine increase pregnancy rate in patients with recurrent implantation failure


Eligibility criteria:
inclusion criteria: * age: 20-39 * previous 3 or more failed ivf exclusion criteria: * intrauterine anomalies * chronic systemic illness * chronic pelvic conditions * sensitivety to azathioprine
coureur study myocardial inflammation in cyclist part 2

Conditions: Myocardial Inflammation

Summary: the study will evaluate myocardial inflammation in cyclists after high intense and sustained exercise. our hypothesis is that strenuous exercise in recreational cyclists may be associated with myocardial inflammation. myocardial fibrosis in asymptomatic athletes is associated with life-threatening arrhythmic events and sudden death. although myocarditis seems to be the most likely underlying cause, it remains unclear if strenuous and sustained physical exercise can cause myocardial inflammation with development of myocyte necrosis and possibly myocardial fibrosis in athletes. nineteen recreational cyclists performing "l'etape du tour (edt) de france" a cycling ride (175 km, 3600 m of positive altitude difference) on july 4 2021 will be included in this study. each participant will complete a detailed questionnaire detailing their training history. all participants will have exercise testing approximately 1 week before the edt stage to set aerobic and anaerobic gas exchange thresholds, as well as vo2max. in part 2 of the study cardiac mri will be performed at rest before the edt cycling ride completion. an ecg registration using a rootirx will be realized during and up to 6 hours after the cycling ride. an echocardiography and cardiac mri will be repeated in each cyclist between 3 and 6 hours after edt cycling ride completion. a blood sample will be obtained at that time after the ride. this time point is chosen based on the highest troponin release that 3 to 6 hours post-exercise would allow a sufficient amount of time for inflammation to develop and be detectable, corresponding with the time when cardiac troponin t is typically detectable and representing the liberation of enzymes from damaged myocytes. finally, a third cardiac mri will be repeated 24 hours after start of the cycling ride to verify the evolution of possible inflammation over this time period.


Eligibility criteria:
inclusion criteria: * recreational cyclists performing the 'étape du tour (edt) de france 2021 ride exclusion criteria: * presence of pre-existing cardiovascular or pulmonary diseases, hypertension, diabetes, peripheral vascular diseases, any inflammatory or auto-immune diseases, active sars-cov-2 infection and the intake of anti-inflammatory drugs.
safety, tolerability and efficacy study of liris® 400 mg in women with interstitial cystitis

Conditions: Interstitial Cystitis

Summary: the purposes of the study is to determine if liris®, an investigational drug-delivery system, is safe and tolerable in women with interstitial cystitis (ic), and to evaluate any change in ic symptoms following liris administration.

the study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned randomly (by chance) to liris 400 mg or liris placebo; subjects who complete this part and are eligible to continue, may participate in the open-label part in which all subjects receive liris 400 mg. in both parts of the study (blinded and open-label), liris is inserted into the bladder during cystoscopy, remains in the bladder for 14 days, and is removed during cystoscopy. in addition to the 14 day period with the liris/liris placebo, there is a screening period of up to 2 weeks and a follow up period of 4 weeks.

Eligibility criteria:
inclusion criteria blinded study: * women age 18 and over * diagnosed with interstitial cystitis as defined by protocol * able to report ic symptoms of bladder pain, voiding habits, as required by protocol, and record in diary * able to comply with visit schedule and diary completion at home open-label extension: * must have completed the blinded study prior to screening for the open-label extension exclusion criteria (blinded and open-label extension): * pregnant or lactating women * history or presence of any condition that would make it difficult to accurately evaluate bladder symptoms * bladder or urethral abnormality that would prevent safe insertion of investigational product * requiring medication not allowed per study protocol
interleukine 6 as a predictor of outcome in mechanically ventilated patients with covid 19

Conditions: Mechanical Ventilation Duration

Summary: serum il-6 levels will be determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions and the normal range is \<10 pg/ml , patients' medical records will be carefully reviewed and analyzed. patient data regarding demographics, comorbidities, signs and symptoms, laboratory results and complications will be collected. the occurrence of complications will be confirmed according to the following criteria: acute respiratory distress syndrome (ards) defined according to the berlin definition


Eligibility criteria:
inclusion criteria: * •age: more than 20 years. * gender: both males and females will be included. * mechanically ventilated patients. * covid 19 confirmed diagnosis exclusion criteria: * •immunocompromised patients. * oxygen saturation more than 95% without ventilation. * malignancy. * patients refuse to be enrolled in the study.
the effects of pistacia mutica on de novo dental plaque formation, gingival inflammation and oral microorganisms

Conditions: Gingivitis

Summary: dental plaque is a well known etiologic factor for gingivitis. recently, herbal extracts are a matter of scientific interest to inhibit plaque accumulation on teeth. the purpose of this study was to evaluate the effects of pistacia mutica (pm) mouth wash on de novo dental plaque plaque formation, gingival inflammation indices and oral microorganisms.


Eligibility criteria:
inclusion criteria: * had merely gingivitis (pocket depth≤3 mm, no attachment loss) * without any fixed or removable oral appliances exclusion criteria: * individuals who had a history of any relevant systemic diseases * individuals who had a history of any drug usage

Keywords: gingivitis dental plaque mouthrinse
impact of double-layer versus single-layer uterine closure suture in cesarean section on the development of postoperative uterine scar deficiency

Conditions: Cesarean Section; Uterine Scar Deficiency; Myometrial Thickness; Single-layer Continuous Uterotomy Suture; Double-layer Continuous Uterotomy Suture; Transvaginal Ultrasound

Summary: in recent decades, the rate of cesarean section delivery has steadily increased worldwide ranging at 30% of deliveries, thus long-term risks after cesarean section need to be evaluated. postoperative risks include, among others, uterine scar rupture and placental complications such as placenta previa and accreta- complications, which are possibly associated with uterine scar dehiscence. the prevalence of lower-segment uterine scar deficiency has previously been described as 63%. one recent systematic review and meta analysis investigated closure techniques of low transverse cesarean. no significant difference in risk of uterine scar defect comparing single layer versus double layer closure could be detected (rr 0.53), whereas in women with single layer closure, a lower residual myo-metrial thickness was observed (-2.6mm). however, the authors do conclude that data is insufficient to determine the risk of uterine rupture, dehiscence or gynecological outcomes due to insufficient power of available studies. a recently published randomized controlled trial concluded that double-layer closure with unlocked first layer showed a better scar healing than locked single layer. the investigators main objective is to identify if single-layer suture of the uterus during cesarean section results in a higher rate of cesarean scar deficiency than double-layer suture. interventions single- layer versus double- layer uterine closure two different techniques of uterine closure in cesarean section will be compared: single- layer versus double- layer continuous uterotomy suture. standardized transvaginal sonography transvaginal ultrasound examination is carried out by one expert sonographer. the ultrasound machine used for all examinations is ge voluson e10. primary outcome: cs scar deficiency visualized in transvaginal ultrasound at 3 months after cs (yes/no). secondary outcome: myometrial thickness at the site of uterine scar (mm).


Eligibility criteria:
inclusion criteria: * first cesarean section * scheduled cesarean section at department of obstetrics and gynecology, medical university of vienna * age ≥ 18 years * informed consent * cesarean section at ≥ 37+0 weeks of gestation exclusion criteria: * previous cesarean section * emergency cesarean section * cesarean section \< 37+0 weeks of gestation * corporal incision during cesarean section * diseases which favor wound healing disruptions (e.g. chronic inflammatory diseases) * uterine anatomic anomalies * bmi \> 35kg/m2 * placenta previa